⌘K
Loading ticker…
As of 2026-08-24, BioXcel Therapeutics, Inc. Common Stock (BTAI) has a 3-month relative strength percentile of 13 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 32. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 9.9%, relative volume 1.29×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
BTAI is in a stage 4 downtrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -23.9% / -45.8%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
BTAI appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $278K notional.
Held by 1 ETFs · $278K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $278K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BTAI Jan avg: 7.12% median: 4.26% win: 50% σ: 19.32% n: 4 2022-04-12 → 2026-07-31 | BTAI Feb avg: -10.72% median: 1.90% win: 50% σ: 32.36% n: 4 2022-04-12 → 2026-07-31 | BTAI Mar avg: -19.66% median: -15.54% win: 0% σ: 15.65% n: 4 2022-04-12 → 2026-07-31 | BTAI Apr avg: -7.34% median: -8.87% win: 20% σ: 10.95% n: 5 2022-04-12 → 2026-07-31 | BTAI May avg: -18.60% median: -13.00% win: 0% σ: 13.07% n: 5 2022-04-12 → 2026-07-31 | BTAI Jun avg: -1.09% median: 12.82% win: 60% σ: 45.39% n: 5 2022-04-12 → 2026-07-31 | BTAI Jul avg: -5.72% median: -12.50% win: 40% σ: 32.61% n: 5 2022-04-12 → 2026-07-31 | BTAI Aug avg: 23.51% median: -28.24% win: 25% σ: 125.35% n: 4 2022-04-12 → 2026-07-31 (current) | BTAI Sep avg: -21.07% median: -23.33% win: 0% σ: 16.91% n: 4 2022-04-12 → 2026-07-31 | BTAI Oct avg: 13.65% median: 7.91% win: 75% σ: 32.79% n: 4 2022-04-12 → 2026-07-31 | BTAI Nov avg: -0.67% median: 2.20% win: 50% σ: 29.55% n: 4 2022-04-12 → 2026-07-31 | BTAI Dec avg: -7.54% median: -15.44% win: 25% σ: 26.19% n: 4 2022-04-12 → 2026-07-31 |